Back to Hematology
Hematologyv2007Evidence-Based

International Prognostic Index for Diffuse Large B-cell Lymphoma (IPI and R-IPI)

Predicts overall and progression-free survival in diffuse large B-cell lymphoma (DLBCL) based on five independent risk factors. The original IPI (International Prognostic Index) was developed in the pre-rituximab era and identifies four risk groups based on age, performance status, disease stage, LDH level, and extranodal involvement. The R-IPI (Revised IPI) was developed for the rituximab era to better discriminate outcomes in patients receiving R-CHOP therapy, redistributing patients into three prognostic groups with improved clinical utility. Both indices provide valuable prognostic information for treatment planning, clinical trial stratification, and patient counseling in DLBCL management.

Clinical Input Parameters

years
sites
Clinical Assessment
Awaiting Parameters
dlbcl ipi score
—points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The International Prognostic Index for Diffuse Large B-cell Lymphoma (IPI and R-IPI) is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within hematology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

IPI Score = Age >60 (1) + LDH elevated (1) + Ann Arbor III/IV (1) + ECOG ≥2 (1) + >1 extranodal site (1). R-IPI redistributes into 3 groups: Very Good (0-1), Good (2), Poor (3-5)

Clinical Pearls & Practice Notes

  • The IPI was originally developed in 1993 before the rituximab era using data from 2031DLBCL patients
  • Five independent risk factors: Age >60 years, LDH above ULN, Ann Arbor stage III/IV, ECOG ≥2, >1 extranodal site
  • Each risk factor contributes 1 point to the total score (range 0-5)
  • Original IPI identifies 4 risk groups: Low (0-1), Low-Int (2), High-Int (3), High (4-5)
  • R-IPI was developed in 2007 for patients receiving rituximab-based therapy (R-CHOP)
  • R-IPI redistributes patients into 3 groups with better discrimination in rituximab era
  • R-IPI Very Good (0-1 points): 4-year PFS 94%, OS 94%
  • R-IPI Good (2 points): Intermediate outcomes between very good and poor groups
  • R-IPI Poor (3-5 points): Lowest survival rates, requires aggressive management
  • LDH elevation reflects tumor burden and proliferative activity
  • ECOG performance status: 0=fully active, 1=restricted strenuous activity, 2=ambulatory >50% time
  • Ann Arbor staging: I/II=limited disease, III/IV=advanced disease
  • Extranodal sites include CNS, bone marrow, liver, lungs, GI tract, bone, kidney
  • The IPI remains useful for treatment planning and clinical trial stratification
  • R-IPI provides better prognostic discrimination in the rituximab era
  • NCCN-IPI may have superior discrimination but uses more complex age stratification
  • Both indices are validated across multiple international cohorts
  • Use for risk stratification, treatment intensity selection, and patient counseling
  • High-risk patients should be considered for clinical trials and intensified therapy
  • CNS prophylaxis may be considered for high-risk patients with specific features
  • Regular reassessment during treatment to monitor response and adjust therapy

Evidence & Literature Citations

  1. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993 Sep 30;329(14):987-94. doi: 10.1056/NEJM199309303291402.
  2. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007 Mar 1;109(5):1857-61. doi: 10.1182/blood-2006-08-038257.
  3. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood. 2020 Jun 11;135(23):2041-2048. doi: 10.1182/blood.2019002729.

Score Interpretation Ranges

Low Risk (IPI) / Very Good (R-IPI)0 – 1 pts

Score 0-1 points

Low-Intermediate Risk (IPI) / Good (R-IPI)2 – 2 pts

Score 2 points

High-Intermediate Risk (IPI) / Poor (R-IPI)3 – 3 pts

Score 3 points

High Risk (IPI) / Poor (R-IPI)4 – 5 pts

Score 4-5 points

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.